Literature DB >> 17764468

Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation.

Raavi Gupta1, Chad P Soupir, Vandita Johari, Robert P Hasserjian.   

Abstract

The present study analysed the clinicopathological features of nine myelodysplastic syndrome (MDS) patients in which del(20q) was the sole cytogenetic abnormality and a control group of 17 adult patients with idiopathic thrombocytopenic purpura (ITP). Seven of nine del(20q) patients were thrombocytopenic and six of nine were mildly anaemic at presentation. There was no significant morphological dysplasia identified in the del(20q) group as compared with the ITP group. These results indicate that MDS with del(20q) commonly presents with thrombocytopenia and has minimal morphological dysplasia. Cytogenetic analysis on adult patients undergoing bone marrow sampling for thrombocytopenia may help avoid misdiagnosis of MDS with del(20q) as ITP.

Entities:  

Mesh:

Year:  2007        PMID: 17764468     DOI: 10.1111/j.1365-2141.2007.06776.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  14 in total

1.  Therapy-related myelodysplastic syndrome presenting as isolated thrombocytopenia following chemotherapy for acute myeloid leukemia in a Chinese child.

Authors:  Li Guo; Hua Song; Junqing Mao; Yongmin Tang
Journal:  Indian J Pediatr       Date:  2013-07-04       Impact factor: 1.967

2.  Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies.

Authors:  C Cameron Yin; Jie Peng; Yu Li; Rashmi Kanagal-Shamanna; Tariq Muzzafar; Courtney DiNardo; Joseph D Khoury; Shaoying Li; L Jeffrey Medeiros; Sa A Wang; Guilin Tang
Journal:  Mod Pathol       Date:  2015-06-05       Impact factor: 7.842

Review 3.  Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics.

Authors:  Aaron C Shaver; Adam C Seegmiller
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

4.  Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia.

Authors:  Julie Waisbren; Shira Dinner; Jessica Altman; Olga Frankfurt; Irena Helenowski; Juehua Gao; Brandon J McMahon; Brady L Stein
Journal:  Int J Hematol       Date:  2016-08-24       Impact factor: 2.490

5.  Persistent clonal cytogenetic abnormality with del(20q) from an initial diagnosis of acute promyelocytic leukemia.

Authors:  Machiko Fujioka; Hidehiro Itonaga; Takeharu Kato; Yasuhito Nannya; Miki Hashimoto; Sachie Kasai; Eo Toriyama; Rena Kamijo; Masataka Taguchi; Hiroaki Taniguchi; Shinya Sato; Sunao Atogami; Yoshitaka Imaizumi; Tomoko Hata; Yukiyoshi Moriuchi; Seishi Ogawa; Yasushi Miyazaki
Journal:  Int J Hematol       Date:  2019-09-12       Impact factor: 2.490

6.  Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk.

Authors:  Liang Li; Min Li; Canlan Sun; Liton Francisco; Sujata Chakraborty; Melanie Sabado; Tinisha McDonald; Janelle Gyorffy; Karen Chang; Shirong Wang; Wenhong Fan; Jiangning Li; Lue Ping Zhao; Jerald Radich; Stephen Forman; Smita Bhatia; Ravi Bhatia
Journal:  Cancer Cell       Date:  2011-11-15       Impact factor: 31.743

7.  Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS.

Authors:  A Porwit; A A van de Loosdrecht; P Bettelheim; L Eidenschink Brodersen; K Burbury; E Cremers; M G Della Porta; R Ireland; U Johansson; S Matarraz; K Ogata; A Orfao; F Preijers; K Psarra; D Subirá; P Valent; V H J van der Velden; D Wells; T M Westers; W Kern; M C Béné
Journal:  Leukemia       Date:  2014-06-12       Impact factor: 11.528

8.  Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.

Authors:  D Caramazza; K H Begna; N Gangat; R Vaidya; S Siragusa; D L Van Dyke; C Hanson; A Pardanani; A Tefferi
Journal:  Leukemia       Date:  2010-10-14       Impact factor: 11.528

9.  Hippo kinase loss contributes to del(20q) hematologic malignancies through chronic innate immune activation.

Authors:  Samuel A Stoner; Ming Yan; Katherine Tin Heng Liu; Kei-Ichiro Arimoto; Takahiro Shima; Huan-You Wang; Daniel T Johnson; Rafael Bejar; Catriona Jamieson; Kun-Liang Guan; Dong-Er Zhang
Journal:  Blood       Date:  2019-11-14       Impact factor: 25.476

10.  Durable hematological and major cytogenetic response in a patient with isolated 20q deletion myelodysplastic syndrome treated with lenalidomide.

Authors:  Bagi Jana; Anas Khanfar; Mary Ninan
Journal:  Case Rep Oncol Med       Date:  2014-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.